CPDD 78th Annual Scientific Meeting Program

Tuesday, June 14
SYMPOSIA
XI.
Not your average joint: Alternative methods of cannabis consumption
Chairs: Adam Leventhal and Marcel O. Bonn-Miller
With increasing legalization of cannabis, there has been a proliferation of the number
and types of cannabis preparations and drug delivery devices available on the market.
Consequently, smoking cannabis is no longer the exclusive route of cannabinoid
consumption prominent in the population. Oral consumption of edible cannabis
products, transdermal application of topical cannabinoid ointments, and vaporization
of cannabis plant, oils, and liquid extracts via e-cigarettes and other electronic devices
are becoming increasingly popular. Unfortunately, many drug dependence researchers,
clinicians, and policy makers are unaware of this trend and the emerging science on
alternative routes of cannabis administration. This symposium synthesizes laboratory,
clinical, and population-based research on the pharmacology, clinical correlates, and
epidemiology of cannabis consumption via alternative routes. Human laboratory
research on the acute pharmacokinetic and pharmacodynamic dose-effects of oral
cannabis will be presented and contrasted to prototypical drug effect profiles of
cannabis smoking. Clinical research pertaining to use of various cannabis preparations
among cannabis-dependent individuals and patients using for therapeutic and
recreational purposes will be discussed. Survey data characterizing cannabis vaping in
adolescent and adult cannabis users will be presented. Also discussed will be the
epidemiology of cannabis use by route of consumption and novel data on the
prevalence and mental health correlates of adolescent cannabis vaping and use of
edible cannabis products. The session will close with a discussion of translation across
basic, clinical, and epidemiologic perspectives, and implications for regulation.
Wednesday, June 15
XII:
Medicinal chemistry of novel kappa opioid receptor ligands
Chairs: F.I. Carroll and Thomas Prisinzano
Every since the discovery of the potent and selective kappa opioid receptor antagonists
nor-BNI and kappa opioid receptor agonist such as U69,593 as well as other
antagonists and agonists of this receptor system there has been continuing interest in
basic medicinal chemistry studies that this receptor plays in numerous biological
processes. Animal behavioral studies have shown that both antagonists and agonists
have high potential for treating substance abuse (nicotine, alcohol, cocaine,
methamphetamine and opiates) as well as other CNS disorders (depression, anxiety,
attention deficit hyperactivity disorder, pain, and others). This symposium will provide
information concerning newer kappa opioid receptor ligands for treating substance
abuse. The presentations will include studies directed towards 1) the effect of
substitution for the tryptophan residue in the natural product CJ-15,208; 2) a better
understanding of the medicinal chemistry properties of salvinorin A and analogs; 3)
the optimization of biased kappa opioid receptor ligands; and 4) the effect of changing
the 3,4-dimethyl-4-(3-hyrroxyphenyl)piperidine part of JDTic on its medicinal
chemistry properties. The basic medicinal chemistry research information presented in
these four presentations will provide a better understanding of how the kappa opioid
receptor target will lead to potential pharmacotherapies for treatment of various
substance abuse problems and other CNS disorders.